News
MOTS-c vs CB4211: Related, Not Interchangeable
CB4211 is a modified relative of MOTS-c. Its early human trial cannot establish a MOTS-c dose, side-effect rate, or expected result.
Read article →-
Saxenda Prescribing Information, in Plain English
Saxenda is a daily liraglutide medicine for weight management. Its label has different dose checks for adults and teenagers, plus warnings that matter at any age.
-
10 Questions to Ask Before DSIP
Ten questions about sleep history, breathing, medicines, past treatment, and expectations that help a provider assess a DSIP request.
-
Should I Take Semax Selank? What a Provider Weighs
A provider starts with your symptoms and current treatment. Small studies of the separate peptides don't settle whether the pair fits you.
-
WOMAC Score Meaning: What the Numbers Tell You
WOMAC tracks arthritis pain, stiffness and daily movement. Its scale matters: a score change describes symptoms, and doesn't prove joint repair.
-
CJC-1295 Ipamorelin Blood Sugar: Can It Rise?
The pair's blood sugar risk has no reliable human percentage. The short studies offer useful context for a conversation about diabetes, medicines and monitoring.
-
Wolverine Peptide Myths: 10 Claims Checked
Animal comparisons and small human reports exist. Neither establishes that the BPC-157 and TB-500 blend improves human recovery or works better than either ingredient alone.
-
PT-141 Skin Darkening: Can the Patches Last?
PT-141 can cause patches of darker skin or gums. The Vyleesi studies show a real pigment signal, with uncertainty about complete fading.
-
Cold Weather Medication Delivery: Freeze Concerns
A prescription left outside in the cold is not automatically ruined. Suspected freezing needs the dispensing pharmacy's review of the product and its journey.
-
GLP-1 Prior Authorization Denied? What Comes Next
The denial reason decides the next step: missing records, an unmet coverage rule, or an excluded benefit. An appeal needs to address that specific issue.
-
Does Semaglutide Cause Bone Loss? What We Know
Bone density can fall during semaglutide-related weight loss. New reviews and the Wegovy label explain why fracture risk needs a more individual answer.
-
GHK-Cu Injection vs Topical: What Studies Show
Creams, serums and wound gels account for most human evidence. Injections haven't been shown to work better, and skin absorption isn't the same as benefit.
-
Thymosin Alpha 1 Hepatitis B: Mixed Trial Results
A Taiwan trial found a delayed improvement in viral blood markers. A U.S. study using an inactive comparison treatment did not confirm a clear benefit.
-
BPC-157 for Back Pain: What the Studies Show
No human trial has tested BPC-157 for back pain. Rat spinal-cord experiments and medical-record reports of human use answer different questions.
-
Can You Take Ibuprofen With Tirzepatide? Key Risks
The labels don't name ibuprofen as an interaction. Dehydration, kidney disease, ulcers, and other medicines can still change the answer.
-
DSIP vs Melatonin: What the Sleep Evidence Shows
Melatonin signals nighttime. DSIP's human sleep evidence is small and mixed, and no human sleep trial shows it works better.
-
MK-677 Study: More Lean Mass, No Strength Gain
The 2008 older-adult trial raised hormone levels and fat-free mass. It didn't show stronger muscles or better everyday physical function.
-
Semaglutide Alcohol Use Disorder Trial: Results
A 48-person trial found less drinking on some measures and lower cravings. It did not establish lasting recovery or a treatment plan for alcohol use disorder.
-
GHK-Cu Wound Healing Study: A Mixed Record
A diabetic-ulcer gel trial reported greater wound shrinkage. Other wound trials complicate the answer, and the findings cannot establish injection benefits.
-
HOMA-IR Explained: What Your Score Means
HOMA-IR estimates insulin resistance from fasting blood sugar and insulin. The formula is simple; interpreting the result takes more than a cutoff.
Page 1 of 26 · 504 articles